Certain studies have shown that specific drugs can upregulate the expression of NKG2D ligands, such as MICA/B and ULBP1‐3, in myeloma cells through DNA damage response pathways mediated by ATM and ATR. This evidence concerns the gene KLRK1 and plasma cell myeloma.